IRVINE, Calif., May 7, 2020 /PRNewswire/ -- Edwards
Lifesciences Corporation (NYSE: EW), the global leader in
patient-focused innovations for structural heart disease and
critical care monitoring, today announced updates from its annual
meeting, in which Edwards' stockholders voted with the board's
recommendations on all proxy proposals.
During the meeting, held earlier today, the company also
announced changes to the company's board of directors.
Wes von Schack, who has been a
director since 2010, has retired from the board and Edwards'
stockholders approved the appointment of Ramona Sequeira to the board. Sequeira is
president of Takeda Pharmaceuticals USA, Inc., and also leads Takeda's global
portfolio commercialization efforts.
"I'd like to take this opportunity to express my sincere
appreciation and gratitude to Wes, who has retired after serving on
Edwards' board for 10 years," said Michael
A. Mussallem, Edwards' chairman and CEO. "Wes was a
substantial contributor to our board, utilizing his decades of
experience as a CEO and board chairman. His engagement and guidance
during a period of significant growth and progress at Edwards have
been valued and admired. We thank Wes for his leadership, service
and contributions."
During von Schack's tenure with the board, he served as
presiding director and then lead independent director. Martha Marsh, a board member since 2015, assumed
the role of lead independent director. Marsh served the
healthcare industry for more than 30 years in a variety of
leadership positions, including as president and CEO of Stanford
Hospital and Clinics and CEO of the University
of California Davis Medical Center.
"Also today, we welcome Ramona to Edwards' board of directors,
and we look forward to her insights as an experienced lifesciences
executive, working around the world to help deliver important
therapies to patients," said Mussallem. "Ramona has a passion for
healthcare innovation and patient access that aligns with the
values and strategy of our company, and we are confident she will
further strengthen our talented and engaged board."
During her more than 20-year career in the pharmaceutical
industry, Sequeira has held leadership roles with Takeda
Pharmaceutical Company and previously with Eli Lilly and Company in
the U.S., Europe and Canada. Currently, she serves as treasurer on
the board of directors of the Pharmaceutical Research and
Manufacturers of America (PhRMA), which represents
biopharmaceutical research companies.
Also at today's annual meeting, stockholders approved the
company's plan to execute a 3-for-1 stock split. The split of the
company's outstanding shares of common stock will be effected in
the form of a stock dividend of two shares of common stock to the
holders of record of each share of Edwards' common stock as of the
close of business on May 18, 2020.
The additional shares will be distributed on May 29, 2020.
The stock split will increase the number of common shares
outstanding from approximately 212 million shares to approximately
636 million shares. The company's last stock split occurred in
December 2015; this will be the
company's third since it went public in April 2000.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the
global leader of patient-focused medical innovations for structural
heart disease and critical care monitoring. We are driven by a
passion for patients, dedicated to improving and enhancing lives
through partnerships with clinicians and stakeholders across the
global healthcare landscape. For more information, visit
Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter
and YouTube.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to execution of the stock
split. Forward-looking statements are based on estimates and
assumptions made by management of the company and are believed to
be reasonable, though they are inherently uncertain and difficult
to predict. Our forward-looking statements speak only as of the
date on which they are made and we do not undertake any obligation
to update any forward-looking statement to reflect events or
circumstances after the date of the statement. Statements of
past performance, efforts, or results about which inferences or
assumptions may be made can also be forward-looking statements and
are not indicative of future performance or results; these
statements can be identified by the use of words such as
"continued," "transform," "develop," "preliminary," "initial,"
diligence," "industry-leading," "compliant," "indications," or
"early feedback" or other forms of these words or similar words or
expressions or the negative thereof. Investors are cautioned
not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors as detailed in the company's filings with the Securities
and Exchange Commission including its Annual Report on Form 10-K
for the year ended December 31, 2019
and the Quarterly Report on Form 10-Q for the quarter ended
March 31, 2020. These filings, along
with important safety information about our products, may be found
at edwards.com.
Edwards, Edwards Lifesciences and the stylized E logo are
trademarks of Edwards Lifesciences Corporation and its affiliates.
All other trademarks are the property of their respective
owners. This statement is made on behalf of Edwards
Lifesciences Corporation and its subsidiaries.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/edwards-announces-updates-from-annual-meeting-301055260.html
SOURCE Edwards Lifesciences Corporation